From: Gastrointestinal Complications (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
·Table 5. Rate of Grade 3 or 4 Diarrhea Associated With Oral Chemotherapya
| Chemotherapy Agent | Grade 3 or 4 Diarrhea Rate (%)b | Reference |
|---|---|---|
| Selumetinib | 24 | [24] |
| Tucatinib (with capecitabine/trastuzumab) | 13 | [27,28] |
| Vandetanib | 10–11 | [29 ,30] |
| Umbralisib | 10 | [31] |
| Vorinostat | 5–8 | [32,33] |
| Sunitinib | 4–10 | [24] |
| Sotorasib | 4 | [34,35] |
| Selinexor | 3–7 | [36-38] |
| Sorafenib | 2–8 | [39 - 41] |
aIncludes drugs with 5% or greater grade 3 or 4 toxicity.
bHighest percentage listed in current manufacturer prescribing information (single-agent rate of diarrhea listed if provided; excludes irinotecan-based combinations).